Determination of girisopam (2,3-benzodiazepine compound) and its four metabolites in human and rat plasma by gradient RP-HPLC method

Iván Ürmös, I. Klebovich, Katalin Balogh Nemes

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A gradient RP-HPLC bioanalytical method has been developed for the human pharmacokinetic studies of girisopam, the new 2,3-benzodiazepine compound with anxiolytic effect that has no myorelaxant and anticonvulsive side effects. The compound is an analogue of tofizopam (Grandaxin®, EGIS Pharmaceuticals Ltd., Budapest, Hungary). The method was found to be appropriate for the purposes of human pharmacokinetic studies performed at 25, 50, 100, 200, 325, and 525 mg dose levels. The method allowed the simultaneous determination of girisopam (G) and its four metabolites (4'- hydroxy-G, 7-demethyl-G, 4-hydroxymethyl-G and 4-demethyl-4-oxo-G) identified in previous studies in human plasma. The solutes were separated on Hypersil BDS C18 column and quantified by UV detection at 238 nm. A solid phase extraction (SPE) method using reversed-phase cartridges was developed for sample processing, whereby girisopam and the much more polar metabolites, as well as the internal standard could be extracted in a single step. The limit of quantitation (LLOQ) was: 1 ng/mL in the case of Girisopam (G), 4- hydroxymethyl-G, 4-demethyl-4-oxo-G and 4'-hydroxy-G. In the case of 7- demethyl-G, LLOQ amounted to 2 ng/mL. The calibration curves showed good linearity; r = 0.9959, 0.9928, 0.9954, and 0.9974 in the concentration range of 1-500 ng/mL and r = 0.9959 in the range of 2-500 ng/mL respectively. The validation results obtained for all the five solutes indicated that the present method complied with internationally accepted criteria and ensured quantitative determinations of appropriate accuracy and reproducibility. After small modification and validation, the developed method was applied for determination of girisopam and its metabolites in rat plasma in a toxicological study (in vivo rat liver micronucleus test) at 600 and 1200 mg/kg dose levels. The LLOQ was 10 ng/mL for girisopam and 50 ng/mL for metabolities in rat plasma. The validation parameters for determination of solutes in rat plasma were internationally acceptable. The linearity was good for all components (r ≤ 0.992) in the wide calibration range of 10-18000 ng/mL and 50-6000 ng/mL in the case of girisopam and its metabolites respectively. The absorption of girisopam was verified by the measuring of girisopam and its metabolite (7-demethyl-G) in the plasma samples of toxicological study (micronucleus test).

Original languageEnglish
Pages (from-to)803-818
Number of pages16
JournalJournal of Liquid Chromatography and Related Technologies
Volume21
Issue number6
Publication statusPublished - 1998

Fingerprint

Metabolites
Benzodiazepines
Rats
High Pressure Liquid Chromatography
Plasmas
Micronucleus Tests
Pharmacokinetics
Toxicology
Calibration
Plasma (human)
girisopam
Hungary
Anti-Anxiety Agents
Solid Phase Extraction
Liver
Processing
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Analytical Chemistry

Cite this

@article{580777e61df54604b613feb2c5b3ba44,
title = "Determination of girisopam (2,3-benzodiazepine compound) and its four metabolites in human and rat plasma by gradient RP-HPLC method",
abstract = "A gradient RP-HPLC bioanalytical method has been developed for the human pharmacokinetic studies of girisopam, the new 2,3-benzodiazepine compound with anxiolytic effect that has no myorelaxant and anticonvulsive side effects. The compound is an analogue of tofizopam (Grandaxin{\circledR}, EGIS Pharmaceuticals Ltd., Budapest, Hungary). The method was found to be appropriate for the purposes of human pharmacokinetic studies performed at 25, 50, 100, 200, 325, and 525 mg dose levels. The method allowed the simultaneous determination of girisopam (G) and its four metabolites (4'- hydroxy-G, 7-demethyl-G, 4-hydroxymethyl-G and 4-demethyl-4-oxo-G) identified in previous studies in human plasma. The solutes were separated on Hypersil BDS C18 column and quantified by UV detection at 238 nm. A solid phase extraction (SPE) method using reversed-phase cartridges was developed for sample processing, whereby girisopam and the much more polar metabolites, as well as the internal standard could be extracted in a single step. The limit of quantitation (LLOQ) was: 1 ng/mL in the case of Girisopam (G), 4- hydroxymethyl-G, 4-demethyl-4-oxo-G and 4'-hydroxy-G. In the case of 7- demethyl-G, LLOQ amounted to 2 ng/mL. The calibration curves showed good linearity; r = 0.9959, 0.9928, 0.9954, and 0.9974 in the concentration range of 1-500 ng/mL and r = 0.9959 in the range of 2-500 ng/mL respectively. The validation results obtained for all the five solutes indicated that the present method complied with internationally accepted criteria and ensured quantitative determinations of appropriate accuracy and reproducibility. After small modification and validation, the developed method was applied for determination of girisopam and its metabolites in rat plasma in a toxicological study (in vivo rat liver micronucleus test) at 600 and 1200 mg/kg dose levels. The LLOQ was 10 ng/mL for girisopam and 50 ng/mL for metabolities in rat plasma. The validation parameters for determination of solutes in rat plasma were internationally acceptable. The linearity was good for all components (r ≤ 0.992) in the wide calibration range of 10-18000 ng/mL and 50-6000 ng/mL in the case of girisopam and its metabolites respectively. The absorption of girisopam was verified by the measuring of girisopam and its metabolite (7-demethyl-G) in the plasma samples of toxicological study (micronucleus test).",
author = "Iv{\'a}n {\"U}rm{\"o}s and I. Klebovich and Nemes, {Katalin Balogh}",
year = "1998",
language = "English",
volume = "21",
pages = "803--818",
journal = "Journal of Liquid Chromatography and Related Technologies",
issn = "1082-6076",
publisher = "Taylor and Francis Ltd.",
number = "6",

}

TY - JOUR

T1 - Determination of girisopam (2,3-benzodiazepine compound) and its four metabolites in human and rat plasma by gradient RP-HPLC method

AU - Ürmös, Iván

AU - Klebovich, I.

AU - Nemes, Katalin Balogh

PY - 1998

Y1 - 1998

N2 - A gradient RP-HPLC bioanalytical method has been developed for the human pharmacokinetic studies of girisopam, the new 2,3-benzodiazepine compound with anxiolytic effect that has no myorelaxant and anticonvulsive side effects. The compound is an analogue of tofizopam (Grandaxin®, EGIS Pharmaceuticals Ltd., Budapest, Hungary). The method was found to be appropriate for the purposes of human pharmacokinetic studies performed at 25, 50, 100, 200, 325, and 525 mg dose levels. The method allowed the simultaneous determination of girisopam (G) and its four metabolites (4'- hydroxy-G, 7-demethyl-G, 4-hydroxymethyl-G and 4-demethyl-4-oxo-G) identified in previous studies in human plasma. The solutes were separated on Hypersil BDS C18 column and quantified by UV detection at 238 nm. A solid phase extraction (SPE) method using reversed-phase cartridges was developed for sample processing, whereby girisopam and the much more polar metabolites, as well as the internal standard could be extracted in a single step. The limit of quantitation (LLOQ) was: 1 ng/mL in the case of Girisopam (G), 4- hydroxymethyl-G, 4-demethyl-4-oxo-G and 4'-hydroxy-G. In the case of 7- demethyl-G, LLOQ amounted to 2 ng/mL. The calibration curves showed good linearity; r = 0.9959, 0.9928, 0.9954, and 0.9974 in the concentration range of 1-500 ng/mL and r = 0.9959 in the range of 2-500 ng/mL respectively. The validation results obtained for all the five solutes indicated that the present method complied with internationally accepted criteria and ensured quantitative determinations of appropriate accuracy and reproducibility. After small modification and validation, the developed method was applied for determination of girisopam and its metabolites in rat plasma in a toxicological study (in vivo rat liver micronucleus test) at 600 and 1200 mg/kg dose levels. The LLOQ was 10 ng/mL for girisopam and 50 ng/mL for metabolities in rat plasma. The validation parameters for determination of solutes in rat plasma were internationally acceptable. The linearity was good for all components (r ≤ 0.992) in the wide calibration range of 10-18000 ng/mL and 50-6000 ng/mL in the case of girisopam and its metabolites respectively. The absorption of girisopam was verified by the measuring of girisopam and its metabolite (7-demethyl-G) in the plasma samples of toxicological study (micronucleus test).

AB - A gradient RP-HPLC bioanalytical method has been developed for the human pharmacokinetic studies of girisopam, the new 2,3-benzodiazepine compound with anxiolytic effect that has no myorelaxant and anticonvulsive side effects. The compound is an analogue of tofizopam (Grandaxin®, EGIS Pharmaceuticals Ltd., Budapest, Hungary). The method was found to be appropriate for the purposes of human pharmacokinetic studies performed at 25, 50, 100, 200, 325, and 525 mg dose levels. The method allowed the simultaneous determination of girisopam (G) and its four metabolites (4'- hydroxy-G, 7-demethyl-G, 4-hydroxymethyl-G and 4-demethyl-4-oxo-G) identified in previous studies in human plasma. The solutes were separated on Hypersil BDS C18 column and quantified by UV detection at 238 nm. A solid phase extraction (SPE) method using reversed-phase cartridges was developed for sample processing, whereby girisopam and the much more polar metabolites, as well as the internal standard could be extracted in a single step. The limit of quantitation (LLOQ) was: 1 ng/mL in the case of Girisopam (G), 4- hydroxymethyl-G, 4-demethyl-4-oxo-G and 4'-hydroxy-G. In the case of 7- demethyl-G, LLOQ amounted to 2 ng/mL. The calibration curves showed good linearity; r = 0.9959, 0.9928, 0.9954, and 0.9974 in the concentration range of 1-500 ng/mL and r = 0.9959 in the range of 2-500 ng/mL respectively. The validation results obtained for all the five solutes indicated that the present method complied with internationally accepted criteria and ensured quantitative determinations of appropriate accuracy and reproducibility. After small modification and validation, the developed method was applied for determination of girisopam and its metabolites in rat plasma in a toxicological study (in vivo rat liver micronucleus test) at 600 and 1200 mg/kg dose levels. The LLOQ was 10 ng/mL for girisopam and 50 ng/mL for metabolities in rat plasma. The validation parameters for determination of solutes in rat plasma were internationally acceptable. The linearity was good for all components (r ≤ 0.992) in the wide calibration range of 10-18000 ng/mL and 50-6000 ng/mL in the case of girisopam and its metabolites respectively. The absorption of girisopam was verified by the measuring of girisopam and its metabolite (7-demethyl-G) in the plasma samples of toxicological study (micronucleus test).

UR - http://www.scopus.com/inward/record.url?scp=0031801918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031801918&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0031801918

VL - 21

SP - 803

EP - 818

JO - Journal of Liquid Chromatography and Related Technologies

JF - Journal of Liquid Chromatography and Related Technologies

SN - 1082-6076

IS - 6

ER -